title: Salvage chemotherapy with mitomycin, vindesine, and cisplatin (MiViP) in recurrent carcinoma of the cervix.
abstract: The combination of mitomycin (8 mg/m(2), i.v., day 1), vindesine (3 mg /m(2), i.v., days 1 and 8), and cisplatin (60 mg/m(2), i.v., day 1) (MiViP) was evaluated in 12 patients with recurrent carcinoma of the cervix. The number of treatment courses ranged from two to eight, with a median of five. Three patients achieved complete remission and six patients showed partial remission, giving and overall response rate of 75%. The median survival was 18 months, with 22 months for responding patients, and 5 months for nonresponding patients (p < 0.01). The major toxicity was myelosuppression. We conclude that MiViP can effectively be used in recurrent carcinoma of the cervix.
authors.affiliation: Departement de Gynecologie et d'Obstetrique, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
authors.forename: J F
authors.initials: JF
authors.lastname: Delaloye
authors.forename: S
authors.initials: S
authors.lastname: Leyvraz
authors.forename: E
authors.initials: E
authors.lastname: Outcha Adjahoto
authors.forename: J
authors.initials: J
authors.lastname: Bauer
authors.forename: P
authors.initials: P
authors.lastname: De Grandi
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D002277:Carcinoma / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D018450:Disease Progression; D005260:Female; D006801:Humans; D008875:Middle Aged; D008937:Mitomycins / Q000008:administration & dosage* / Q000009:adverse effects; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D012074:Remission Induction; D016879:Salvage Therapy; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*; D014751:Vindesine / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D008937:Mitomycins; D002945:Cisplatin; D014751:Vindesine